Pharmacokinetics of Fluvoxamine in Relation to CYP2C19 Phenotype and Genotype

OBJECTIVE To evaluate the pharmacokinetics of fluvoxamine (FLV) in poor metabolizers (PMs) versus extensive metabolizers (EMs) of cytochrome P450 (CYP)2C19. METHODS This was a prospective, open-label study conducted at the Clinical Research Unit School of Pharmacy. Fifty-seven healthy, nonsmoking volunteers aged 21-40 years participated. Subjects abstained from caffeinated products 12 hours prior to and during each testing period. To assess CYP2C19 activity, blood samples were collected from each subject prior to and two hours after a single dose of omeprazole 20 mg. Once PMs were identified, a sample population of EMs were selected for comparison between the two groups regarding FLV disposition. A single 100 mg FLV dose was given to EMs and PMs; blood samples for FLV analysis were obtained prior to drug administration and 0.5, 1, 2, 3, 4 6, 8, 12 and 24 hours later. A blood sample one day prior to FLV administration was also obtained for CYP2C 19 and CYP2D6. RESULTS Four PMs were identified with the omeprazole phenotype probe and had a mean +/- SD hydroxylation index of 1.335 +/- 0.271. Nine EMs were selected based upon a hydroxylation index between 0.100 and 0.400 (mean 0.193 +/- 0.079). FLV pharmacokinetic parameters (AUC, elimination half-life, Cmax and Tmax) did not significantly differ between the two groups. Genotype analysis for CYP2C19 revealed a mutant allele for the *2 which confirmed phenotype detection of PM status. Genotype analysis for CYP2D6*3 and *4 alleles showed that all PMs of CYP2C19 were EMs of CONCLUSIONS FLV disposition and dosing is unlikely to be affected by CYP2C19 polymorphism.

[1]  Zhaoqian Liu,et al.  Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19 , 2001, Clinical pharmacology and therapeutics.

[2]  N. Klitgaard,et al.  Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide , 2001, Clinical pharmacology and therapeutics.

[3]  M. Dahl,et al.  Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. , 2000, Therapeutic drug monitoring.

[4]  Hong-Guang Xie,et al.  Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects , 1999 .

[5]  K. Otani,et al.  Effects of the CYP2D6*10 allele on the steady‐state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia , 1999, Clinical pharmacology and therapeutics.

[6]  C. Naranjo,et al.  Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. , 1998, Journal of clinical psychopharmacology.

[7]  M. Dahl,et al.  Pharmacogenetics of antidepressants: clinical aspects , 1997, Acta psychiatrica Scandinavica. Supplementum.

[8]  H. Zhou,et al.  In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. , 1996, British journal of clinical pharmacology.

[9]  C. Alm,et al.  Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity , 1996, Clinical pharmacology and therapeutics.

[10]  J. Balian,et al.  Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype , 1996, Clinical pharmacology and therapeutics.

[11]  L. Bertilsson,et al.  Geographical/Interracial Differences in Polymorphic Drug Oxidation , 1995, Clinical pharmacokinetics.

[12]  L. Pickle,et al.  The hydroxylation of omeprazole correlates with S‐mephenytoin metabolism: A population study , 1995, Clinical pharmacology and therapeutics.

[13]  Devane Cl.  Pharmacogenetics and Drug Metabolism of Newer Antidepressant Agents , 1994 .

[14]  E. Perucca,et al.  Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers , 1994, Clinical pharmacology and therapeutics.

[15]  E. Perucca,et al.  Clinical Pharmacokinetics of Fluvoxamine , 1994, Clinical pharmacokinetics.

[16]  T. Andersson,et al.  Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. , 1994, Therapeutic drug monitoring.

[17]  S. Loft,et al.  Fluvoxamine is a potent inhibitor of cytochrome P4501A2. , 1993, Biochemical pharmacology.

[18]  R. H. Pullen,et al.  Determination of fluvoxamine in human plasma by high-performance liquid chromatography with fluorescence detection. , 1992, Journal of chromatography.

[19]  U. Meyer,et al.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.

[20]  P. Stolley,et al.  Sample size calculations for clinical pharmacology studies , 1986, Clinical pharmacology and therapeutics.

[21]  J. Menke.  Drug interactions and the cytochrome P-450 system. , 2000, South Dakota journal of medicine.

[22]  O. Spigset,et al.  Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms , 1997, European Journal of Clinical Pharmacology.

[23]  S. Loft,et al.  Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine , 1996, European Journal of Clinical Pharmacology.

[24]  D. Flockhart,et al.  Drug Interactions and the Cytochrome P450 System , 1995, Clinical pharmacokinetics.